45170-31-8

Basic information

• Product Name: Boc-N-methyl-L-valine
• Synonyms: BOC-N-METHYL-L-VAL-OH;BOC-N-METHYL-L-VALINE;BOC-N-ME-VALINE;BOC-N-ME-VAL-OH;BOC-MEVAL-OH;BOC-N-ALPHA-METHYL-L-VALINE;BOC-L-MEVAL-OH;N-ALPHA-T-BOC-N-ALPHA-METHYL-L-VALINE
• CAS NO: 45170-31-8
• Molecular Formula: C₁₁H₂₁NO₄
• Molecular Weight: 231.29
• Product Categories: Valine [Val, V];N-Methyl Amino Acids;Boc-Amino acid series;amino acids
• Mol File: 45170-31-8.mol

Chemical Properties

• Melting Point: 45-60°C
• Boiling Point: 322.4 °C at 760 mmHg
• Flash Point: 148.8 °C
• Appearance: /Solid
• Density: 1.069 g/cm³
• Vapor Pressure: 5.74E-05mmHg at 25°C
• Refractive Index: 1.466
• Storage Temp.: Store at RT.
• Solubility: Chloroform (Slightly), Ethanol (Slightly), Methanol (Slightly)
• PKA: 4.03±0.10(Predicted)
• BRN: 2646180
• CAS DataBase Reference: Boc-N-methyl-L-valine(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-N-methyl-L-valine(45170-31-8)
• EPA Substance Registry System: Boc-N-methyl-L-valine(45170-31-8)

Safety Data

• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 45170-31-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Boc-N-methyl-L-valine is used as a pharmaceutical intermediate for the development of various drugs. Its unique structure allows it to be a key component in the synthesis of complex molecules with potential therapeutic applications.
Used in Organic Synthesis:
Boc-N-methyl-L-valine is used as a reagent in organic synthesis, where it contributes to the formation of complex organic compounds. Its versatility in chemical reactions makes it a valuable tool for researchers and chemists working on the development of new molecules.
Used in Antitumor Chemotherapy:
Boc-N-methyl-L-valine is used in the synthesis of lactam analogs of actinomycin D, which are potential antitumor chemotherapeutic agents. Its role in the development of these agents highlights its importance in the fight against cancer.

InChI:InChI=1/C11H21NO4/c1-7(2)8(9(13)14)12(6)10(15)16-11(3,4)5/h7-8H,1-6H3,(H,13,14)/t8-/m1/s1

Upstream product

• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 2480-23-1 N-methyl-L-valine 
• 13734-41-3 t-Boc-L-valine 
• 74-88-4 methyl iodide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 6306-52-1 L-valine methylester hydrochloride 
• 58561-04-9 N-tert-butoxycarbonyl-L-valine methyl ester 
• 24164-06-5 methyl (2S)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-methylbutanoate 
• 640-68-6 D-Val-OH 
• 22838-58-0 Boc-D-Val-OH 
• 124-38-9 carbon dioxide 
• 140175-19-5 Methyl-((S)-2-methyl-1-tributylstannanyl-propyl)-carbamic acid tert-butyl ester 
• 72-18-4 L-valine 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 203646-36-0 O-(tert-butoxycarbonyl)-N-methylvalyl-N-(benzyloxycarbonyl)threonyl-D-phenylalaninylprolylsarcosine tert-butyl ester 
• 174602-80-3 benzyl (2S)-2-[[(tert-butoxy)carbonyl](methyl)amino]-3-methylbutanoate 
• 639457-70-8 2-[2-(tert-butoxycarbonyl-methyl-amino)-3-methyl-butyrylamino]-3-[2-(3-methyl-but-2-enyl)-1-(toluene-4-sulfonyl)-1H-indol-3-yl]-propionic acid methyl ester 
• 863781-50-4 Boc-Val(N-Me)-Leu-Phe-OMe 
• 89536-89-0 benzyl (2S)-3-methyl-2-(methylamino)butanoate hydrochloride 
• 194933-50-1 microcolin C 
• 194933-48-7 (S)-2-[((2S,3R)-3-Benzyloxy-2-{(S)-2-[((2R,4R)-2,4-dimethyl-octanoyl)-methyl-amino]-4-methyl-pentanoylamino}-butyryl)-methyl-amino]-3-methyl-butyric acid methyl ester 
• 194933-49-8 (S)-2-[((2S,3R)-3-Benzyloxy-2-{(S)-2-[((2R,4R)-2,4-dimethyl-octanoyl)-methyl-amino]-4-methyl-pentanoylamino}-butyryl)-methyl-amino]-3-methyl-butyric acid 
• 194933-47-6 (S)-2-({(2S,3R)-3-Benzyloxy-2-[(S)-2-(tert-butoxycarbonyl-methyl-amino)-4-methyl-pentanoylamino]-butyryl}-methyl-amino)-3-methyl-butyric acid methyl ester 
• 194933-46-5 (S)-2-[((2S,3R)-3-Benzyloxy-2-tert-butoxycarbonylamino-butyryl)-methyl-amino]-3-methyl-butyric acid methyl ester 
• 3339-44-4 methyl N-methyl-L-valinate hydrochloride 

Relevant articles and documents

Synthetic studies on quinoxaline antibiotics: II. Synthesis of triostin A

Triostin A, a cyclic octadepsipeptide, was synthesized with Z-D-Ser[Boc-Ala-MeCys(Bzl)-MeVal]-OH and Z-n-Ser[H-Ala-MeCys(Bzl)-MeVal]-OTce as key intermediates. The synthetic antibiotic was compared with natural triostin A in terms of chromatographic behaviors, NMR spectra, and antomicrobial activity to establish their identity. The NMR data on S,S'-dibenzyldihydrotriostin A showed that this intermediate lacking the disulfide linkage also existed as two conformers in chloroform. This observation excludes the possibility that the conformer equilibrium known to occur with triostin A is a consequence of the reversed chirality of the disulfide bond. Triostin A, a cyclic octadepsipeptide, was synthesized with Z-D-Ser left bracket Boc-Ala-MeCys(Bzl)-MeVal right bracket -OH and Z- D-Ser left bracket H-Ala-MeCys(Bzl)-MeVal right bracket -OTce as key intermediates. The synthetic antibiotic was compared with natural triostin A in terms of chromatographic behaviors, NMR spectra, and antimicrobial activity to establish their identity. The NMR data on S,S prime -dibenzyldihydrotriostin A showed that this intermediate lacking the disulfide linkage also existed as two conformers in chloroform. This observation excludes the possibility that the conformer equilibrium known to occur with triostin A is a consequence of the reversed chirality of the disulfide bond.

First total synthesis of hoshinoamide A

Hoshinoamides A, B and C, linear lipopeptides, were isolated from the marine cyanobacterium Caldora penicillata, with potent antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum. Herein, we describe the first total synthesis of hosh

NOVEL CONNECTED BODY AND USE THEREOF IN SPECIFIC CONJUGATION BETWEEN BIOMOLECULE AND DRUG

PROBLEM TO BE SOLVED: To provide: a method for producing a connected body; a method for using the connected body in the production of a uniform conjugate; and a method for applying the conjugate in the treatment of cancer, infectious diseases, and autoimmune diseases. SOLUTION: A novel connected body is provided that includes a 2,3-di-substituted succinic acid group or a 2-mono-substituted or 2,3-di-substituted fumaric acid or maleic acid (trans (E)- or cis (Z)-butenedioic acid) group for conjugating 2 or more compounds/cytotoxic agents per connected body with a cell-binding molecule by specifically bridge-linking to a pair of thiol on the cell-binding molecule. The connected body is exemplified by the following general formula. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

Isolation and Total Synthesis of Kinenzoline, an Antitrypanosomal Linear Depsipeptide Isolated from a Marine Salileptolyngbya sp. Cyanobacterium

Kinenzoline (1), a new linear depsipeptide, was isolated from a marine Salileptolyngbya sp. cyanobacterium. Its structure was elucidated by spectroscopic analyses and degradation reactions. In addition, we achieved a total synthesis of 1 and confirmed its structure. Kinenzoline (1) showed highly selective antiproliferative activity against the causative organism of sleeping sickness, Trypanosoma brucei rhodesiense (IC50 4.5 μM), compared to normal human cells (WI-38, IC50 > 100 μM). Kinenzoline (1) is a promising lead compound for the development of new antitrypanosomal drugs.

CONJUGATION LINKERS CONTAINING 2,3-DIAMINOSUCCINYL GROUP

Provided is a conjugate of a cytotoxic drug/molecule to a cell-binding molecule with a bis-linker (adual-linker) containing a 2, 3-diaminosuccinyl group. It also relates to preparation of the conjugate of a cytotoxic drug/molecule to a cell-binding molecule with the bis-linker, particularly when the drug having functional groups of amino, hydroxyl, diamino, amino-hydroxyl, dihydroxyl, carboxyl, hydrazine, aldehyde and thiol for conjugation with the bis-linker in a specific manner, as well as the therapeutic use of the conjugates.

Benzoazepine-Fused Isoindolines via Intramolecular (3 + 2)-Cycloadditions of Azomethine Ylides with Dinitroarenes

Aminobenzaldehydes bearing a pendant 3,5-dinitrophenyl group react thermally with N-substituted α-amino acids to form unprecedented benzoazepine-fused isoindolines. The reaction proceeds via a dearomatization/rearomatization sequence involving an intramolecular (3 + 2)-cycloaddition between the in situ formed azomethine ylide and the dinitroarene. Various glycine derivatives are tolerated as well as branched substrates based on cyclic, α-mono-, and α,α-disubstituted amino acids, giving single diastereomers in many cases. The method is scalable and gives products with a nitro group ready for further manipulation.

Synthesis of Majusculamides A and B

The synthesis of two marine lipodipeptides, majusculamides A and B, is described. The key feature of this synthesis is the stereoselective construction of an α-methyl-β-keto-carboxamide moiety.

CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE

What provided is the conjugation of cytotoxic to a cell-binding molecule with a bis-linker(dual-linker) as shown in Formula (I). It provides bis-linkage methods of making a conjugate of a cytotoxic drug molecule to a cell-binding agent in a specific manner. It also relates to application of the conjugates for the treatment of a cancer, or an autoimmune disease, or an infectious disease.

CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LIKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS

The present invention relates to linkers having a group of propiolyl, substituted acryl (acryloyl), or disubstituted propanoyl, and using such linkers for the conjugation of compounds, in particular, cytotoxic agents to a cell-binding molecule.

Total synthesis and biological activity of dolastatin 16

The total synthesis of dolastatin 16, a macrocyclic depsipeptide first isolated from the sea hare Dolabella auricularia as a potential antineoplastic metabolite by Pettit et al., was achieved in a convergent manner. Dolastatin 16 was reported by Tan to ex